[Image]

Debashis Sahoo, PhD

Assistant Professor
Department of Pediatrics
Department of Computer Science and Engineering
University of California San Diego
[Logo]
9500 Gilman Drive, MC 0984
Biomedical Research Facility II, Room 2119
La Jolla, CA 92093-0984
Phone: 858-246-1803
Fax: 858-246-0019
7910 Frost Street, Suite 300
Room 371
San Diego, CA 92123
Phone: 858-246-1803
Fax: 858-246-0019
Emails:

Postdoc:
Instructor of Pathology and Siebel Fellow at
Institute of Stem Cell Biology and Regenerative Medicine
Stanford University, Stanford, CA 94305-5461

Education:
Ph.D. 2008, M.S. 2003 BTech 2000
Department of Electrical Engineering
Stanford University
Stanford, CA 94305 (USA)
Department of Computer Science and Engineering
Indian Institute of Technology
Kharagpur-721302, (India)

Ph.D. Thesis: Boolean analysis of high-throughput biological datasets
Ph.D. University/Date: Stanford University, September 25, 2008
Ph.D. Advisor: David L. Dill, Co-advisor: Sylvia K. Plevritis

List of publications

Research:
My research is on developing new methods to analyze high-throughput biological datasets. I have developed several tools and techniques to analyze large collections of microarray datasets. I have made specific biological predictions and then validated them in collaborations with several biologists at Stanford. Some of my tools that analyze gene expression datasets are StepMiner, BooleanNet and MiDReG .
Teaching (Stanford):
  • StemRem 201 - Fall 2013
  • StemRem 201 - Fall 2012
  • Teaching (UCSD):
  • CSE100: Advanced Data Structures (Spring 2015)
  • CSE100: Advanced Data Structures (Fall 2015)
  • CSE100: Advanced Data Structures (Fall 2016)

  • News:
  • [NEJM] CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer
  • [UCSD] New Biomarker Identifies Colon Cancer Patients Who May Benefit from Chemotherapy. Colon cancer patients lacking the protein CDX2 have a poorer prognosis than patients with CDX2 but in some cases are more likely to benefit from chemotherapy.
  • [CUMC] Biomarker Predicts Which Stage II Colon Cancer Patients May Benefit from Chemotherapy. Biomarker is detectable with simple, inexpensive test.
  • [Stanford] Chemotherapy may benefit subgroup of stage-2 colon cancer patients. A small subset of colon cancers lacks the CDX2 protein -- a hallmark of colon tissue maturation. Patients with these cancers may benefit more than others from chemotherapy.

  • My Favorite Links Highlights